United States securities and exchange commission logo





                               September 16, 2020

       RA Session, II
       President and Chief Executive Officer
       Taysha Gene Therapies, Inc.
       2280 Inwood Road
       Dallas, TX 75235

                                                        Re: Taysha Gene
Therapies, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed September 8,
2020
                                                            File No. 333-248559

       Dear Mr. Session:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response. After reviewing any amendment to your registration statement
and the information
       you provide in response to these comments, we may have additional
comments.

       Amendment No. 1 to Registration Statement on Form S-1 filed September 8,
2020

       Our Pipeline, page 2

   1.                                                   We note your response
to prior comment 3 and reissue our comment. Please revise your
                                                        table to depict the
current status of your product candidates in a manner that is consistent
                                                        with the regulatory
process for drug development. Including the following changes:

                                                              We will not
object to separate columns for discovery and preclinical, but object to the
                                                            a separate column
for "construct selection" as that should be considered part of the
                                                            discovery and/or
preclinical work.
                                                              The Term
"IND-enabling" assumes the outcome of the preclinical work, as the FDA
                                                            will determine
whether the results of the preclinical activities support an IND. Please
                                                            revise your table
to clarify that the second column refers to preclinical work.
                                                              With respect to
the column heading "Pivotal Trial," our concern is that the table
                                                            depicts the status
of the product candidate in a manner that is not consistent with the
 RA Session, II
Taysha Gene Therapies, Inc.
September 16, 2020
Page 2
           regulatory process for drug development with separate column for
phases 1, 2 and 3.
           We will not object to columns for phase 1/2 and/or 2/3 trials if the
trials are designed
           to meet the requirements of both phases represented.
             With respect to "Clinical expected..." text for TSHA-101,
TSHA-102, TSHA-103 and
           TSHA-104, please revise to indicate when you expect to file an IND.
To the extent
           you have already submitted an IND, we have no further concerns with
respect to the
           current disclosure.
History and Team, page 7

2.    We note your response to comment 7. As noted in your response, the
identification
      appears to suggest that potential investors may consider investments made
by these
      institutional investors as a factor in making their investment decisions
without knowing
      the amount of their investment in total or on a per share basis, their
investment strategies
      or whether these institutional investors continue to hold their shares.
Additionally, as
      these shareholders are not subject to the reporting requirements of
Section 16, investors
      will not know when they decide to sell their shares. Therefore, we
continue to believe the
      disclosure is inappropriate for the registration statement.
Exhibits

3.    Please file the employment agreement or offer letter, as applicable, with
each of Kamran
      Alam and Suyash Prasad as exhibits to your registration statement.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Li Xiao at 202-551-4391 or Angela Connell at
202-551-3426 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Alan Campbell at 202-551-4224 or Suzanne Hayes at 202-551-3675 with any
other
questions.



                                                             Sincerely,
FirstName LastNameRA Session, II
                                                             Division of
Corporation Finance
Comapany NameTaysha Gene Therapies, Inc.
                                                             Office of Life
Sciences
September 16, 2020 Page 2
cc:       Madison Jones
FirstName LastName